Literature DB >> 23900756

Cerebral FDG-PET and MRI findings in autoimmune limbic encephalitis: correlation with autoantibody types.

Annette Baumgartner1, Sebastian Rauer, Irina Mader, Philipp T Meyer.   

Abstract

In parallel to the detection of new neuronal autoantibodies, the diagnosis of non-infectious limbic encephalitis has risen. Given that cerebral imaging studies show highly variable results, the present retrospective study investigates imaging findings in association with autoantibody type. An institutional database search identified 18 patients with non-infectious limbic encephalitis who had undergone [18F] fluorodeoxyglucose positron emission tomography (FDG-PET). Sixteen of these patients also underwent magnetic resonance imaging (MRI). MRI and FDG-PET images were categorized as follows: normal (0); mesiotemporal abnormality (1); normal mesiotemporal finding but otherwise abnormal (2). Neuronal autoantibodies were determined in serum and/or CSF. Autoantibodies were grouped according to the cellular localization of their target antigen: antibodies against surface antibodies (i.e., VGKC, NMDAR): 9; antibodies against intracellular antigens (i.e., Hu, Ri, GAD): 4; no autoantibodies: 5. The fraction of abnormal scans was lower for MRI (10/16) than for FDG-PET (14/18). There was a significant association between PET findings and autoantibody type: All patients with autoantibodies against intracellular antigens showed mesiotemporal findings on FDG-PET. In turn, only 2/9 patients with autoantibodies against surface antigens displayed mesiotemporal hypermetabolism. In the remaining seven patients, four scans were rated as normal and three only showed findings outside the mesiotemporal region. A similar association was found using MRI, although this did not reach statistical significance. Autoantibody type was found to be associated with FDG-PET and, to a lesser extent, with MRI imaging results. Our observations may explain the heterogeneity of imaging data in LE and based on in vivo findings support the assumption of different patho mechanisms underlying LE due to antibodies against surface and intracellular antigens, respectively.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23900756     DOI: 10.1007/s00415-013-7048-2

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  35 in total

1.  Limbic encephalitis: comparison of FDG PET and MR imaging findings.

Authors:  J M Provenzale; D P Barboriak; R E Coleman
Journal:  AJR Am J Roentgenol       Date:  1998-06       Impact factor: 3.959

2.  Antibodies to glutamic acid decarboxylase define a form of limbic encephalitis.

Authors:  Michael P Malter; Christoph Helmstaedter; Horst Urbach; Angela Vincent; Christian G Bien
Journal:  Ann Neurol       Date:  2010-04       Impact factor: 10.422

3.  Limbic encephalitis investigated by 18FDG-PET and 3D MRI.

Authors:  J Kassubek; F D Juengling; E U Nitzsche; C H Lücking
Journal:  J Neuroimaging       Date:  2001-01       Impact factor: 2.486

4.  Striatal hypermetabolism in limbic encephalitis.

Authors:  Caroline Rey; Lejla Koric; Eric Guedj; Olivier Felician; Elsa Kaphan; José Boucraut; Mathieu Ceccaldi
Journal:  J Neurol       Date:  2011-11-12       Impact factor: 4.849

5.  Anti-NMDA receptor encephalitis presenting with imaging findings and clinical features mimicking Rasmussen syndrome.

Authors:  Hansel Greiner; James L Leach; Ki-Hyeong Lee; Darcy A Krueger
Journal:  Seizure       Date:  2010-12-10       Impact factor: 3.184

Review 6.  Serial 18F-fluoro-2-deoxy-D-glucose positron emission tomography and magnetic resonance imaging of paraneoplastic limbic encephalitis.

Authors:  Rainer Scheid; Thomas Lincke; Raymond Voltz; D Yves von Cramon; Osama Sabri
Journal:  Arch Neurol       Date:  2004-11

7.  Novel FDG-PET findings in anti-NMDA receptor encephalitis: a case based report.

Authors:  Mohsin Maqbool; Deanna A Oleske; A H M Huq; Bassel A Salman; Kevin Khodabakhsh; Harry T Chugani
Journal:  J Child Neurol       Date:  2011-05-19       Impact factor: 1.987

8.  Acute limbic encephalitis and glutamic acid decarboxylase antibodies: a reality?

Authors:  F Blanc; E Ruppert; C Kleitz; M P Valenti; B Cretin; R L Humbel; J Honnorat; I J Namer; E Hirsch; L Manning; J de Seze
Journal:  J Neurol Sci       Date:  2009-09-27       Impact factor: 3.181

9.  N-methyl-D-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes.

Authors:  Sarosh R Irani; Katarzyna Bera; Patrick Waters; Luigi Zuliani; Susan Maxwell; Michael S Zandi; Manuel A Friese; Ian Galea; Dimitri M Kullmann; David Beeson; Bethan Lang; Christian G Bien; Angela Vincent
Journal:  Brain       Date:  2010-06       Impact factor: 13.501

10.  Fluorodeoxyglucose positron emission tomography in anti-N-methyl-D-aspartate receptor encephalitis: distinct pattern of disease.

Authors:  Frank Leypoldt; Ralph Buchert; Ingo Kleiter; Jörg Marienhagen; Mathias Gelderblom; Tim Magnus; Josep Dalmau; Christian Gerloff; Jan Lewerenz
Journal:  J Neurol Neurosurg Psychiatry       Date:  2012-05-07       Impact factor: 10.154

View more
  52 in total

Review 1.  Neuronal surface antibody-mediated autoimmune encephalitis.

Authors:  Jenny J Linnoila; Myrna R Rosenfeld; Josep Dalmau
Journal:  Semin Neurol       Date:  2014-11-04       Impact factor: 3.420

Review 2.  Acute encephalitis - diagnosis and management.

Authors:  Mark Ellul; Tom Solomon
Journal:  Clin Med (Lond)       Date:  2018-03       Impact factor: 2.659

3.  Autoimmune encephalitis mimicking Creutzfeldt-Jakob disease.

Authors:  Olga P Fermo; Izlem Izbudak; Raoul Sutter; Arun Venkatesan; Peter W Kaplan; John C Probasco
Journal:  Neurol Clin Pract       Date:  2014-12

4.  [Autoantibody-associated schizophreniform psychoses: pathophysiology, diagnostics, and treatment].

Authors:  Ludger Tebartz van Elst; Karl Bechter; Harald Prüss; Alkomiet Hasan; Jo Hann Steiner; Frank Leypoldt; Dominique Endres
Journal:  Nervenarzt       Date:  2019-07       Impact factor: 1.214

5.  The need of standardization and of large clinical studies in an emerging indication of [18F]FDG PET: the autoimmune encephalitis.

Authors:  Silvia Morbelli; Javier Arbizu; Jan Booij; Ming-Kai Chen; Gael Chetelat; Donna J Cross; Mehdi Djekidel; Alexander Drzezga; Ozgul Ekmekcioglu; Valentina Garibotto; Swen Hesse; Kazunari Ishii; Lida Jafari; Adriaan A Lammertsma; Ian Law; Dana Mathews; Satoshi Minoshima; Karina Mosci; Marco Pagani; Sabina Pappata; Daniel Hillel Silverman; Alberto Signore; Elsmarieke Van De Giessen; Victor Villemagne; Henryk Barthel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-12-06       Impact factor: 9.236

Review 6.  Autoimmune Encephalitis: Pathophysiology and Imaging Review of an Overlooked Diagnosis.

Authors:  B P Kelley; S C Patel; H L Marin; J J Corrigan; P D Mitsias; B Griffith
Journal:  AJNR Am J Neuroradiol       Date:  2017-02-09       Impact factor: 3.825

7.  Semi-quantitative analysis of cerebral FDG-PET reveals striatal hypermetabolism and normal cortical metabolism in a case of VGKCC limbic encephalitis.

Authors:  Patrick Moloney; Ruth Boylan; Marwa Elamin; Sean O'Riordan; Ronan Killeen; Christopher McGuigan
Journal:  Neuroradiol J       Date:  2017-01-01

8.  Supratentorial white matter blurring associated with voltage-gated potassium channel-complex limbic encephalitis.

Authors:  H Urbach; S Rauer; I Mader; S Paus; J Wagner; M P Malter; H Prüss; J Lewerenz; J Kassubek; H Hegen; M Auer; F Deisenhammer; F Ufer; C G Bien; A Baumgartner
Journal:  Neuroradiology       Date:  2015-08-21       Impact factor: 2.804

9.  Metabolic topography of autoimmune non-paraneoplastic encephalitis.

Authors:  Madhavi Tripathi; Manjari Tripathi; Shambo Guha Roy; Girish Kumar Parida; Kavish Ihtisham; Deepa Dash; Nishikant Damle; Shamim Ahmed Shamim; Chandrasekhar Bal
Journal:  Neuroradiology       Date:  2017-12-18       Impact factor: 2.804

10.  Update on the diagnosis and management of autoimmune encephalitis.

Authors:  Mark A Ellul; Greta Wood; Harriet Van Den Tooren; Ava Easton; Ashik Babu; Benedict D Michael
Journal:  Clin Med (Lond)       Date:  2020-07       Impact factor: 2.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.